Empire Financial Management Company LLC Sells 23,109 Shares of Pfizer Inc. (NYSE:PFE)

Empire Financial Management Company LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 24.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,195 shares of the biopharmaceutical company's stock after selling 23,109 shares during the quarter. Empire Financial Management Company LLC's holdings in Pfizer were worth $1,915,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new stake in Pfizer in the fourth quarter valued at $31,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer in the 4th quarter worth $33,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Stock Up 0.7 %

Shares of NYSE PFE traded up $0.17 during midday trading on Friday, hitting $22.95. The stock had a trading volume of 35,816,572 shares, compared to its average volume of 40,554,243. The company has a market cap of $130.16 billion, a P/E ratio of 16.28, a PEG ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business's 50 day moving average is $24.58 and its 200-day moving average is $25.97. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business posted $0.10 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.49%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is currently 121.99%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PFE. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday. They issued a "neutral" rating and a $24.00 target price for the company. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, UBS Group decreased their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.57.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.